A team led by Dr. Yuri Tolkach at the University of Cologne's Faculty of Medicine and University Hospital Cologne has ...

Medically reviewed by Amelia MacIntyre, DO Approximately 1 in 8 people with a prostate are diagnosed with prostate cancer ...

“The MMAI risk classifier is a more precise and accurate prognosticator of metastasis than NCCN risk groups,” Dr Tward’s team wrote. “This approach aims to prevent both overtreatment and ...

The following is dedicated to our health care workers who looked after me on my prostate journey.

In 2010, a 61-year-old man diagnosed with low-risk, early-stage (Gleason 6) prostate cancer enrolled in a clinical trial designed to compare outcomes of active surveillance vs definitive treatment.

The trial, conducted across 38 centres, included 874 men with stage T1 or T2 prostate cancer, Gleason scores of 3+4 or lower ... slightly higher than the 94.6% in the conventional radiotherapy group, ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in ...

A precursor of vitamin K may help slow down prostate cancer progression, a recent study conducted in mouse models of suggests ...

“Al-determined tumor volume has the potential to advance precision medicine for patients with prostate cancer by improving our ability to understand the aggressiveness of a patient's cancer and ...

If you have any of these signs, you should see your doctor as soon as possible. Learn more about prostate cancer from the National Cancer Institute. Huntsman Cancer Institute’s Urologic Cancers ...

The new therapy combines two existing cancer drugs, enzalutamide and talazoparib. Enzalutamide, known by its brand name XTANDI, has been used as a treatment for metastatic castration-resistant ...